Glenmark Specialty S.A.

ALZUO

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device;

ANETYO

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

ARLUMERE

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; pharmaceutical preparations and substances for the treatment and/or alleviation of respiratory diseases;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device; Nebulizers for respiratory therapy;

ARLUMERE

Antihistamines, nasal steroids, and nasal spray preparations for treatment of respiratory disorders;

AYRLIMA

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

COMCORLA

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments;

EXYRSAIR

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments;

LARAYDA

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments;

LENKLYRA

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device;

MOLIZMA

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

OLIZAERO

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

OLIZAIRA

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

OLIZAYR

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

OMSPRYA

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder, pharmaceutical preparations and substances for the treatment and/or alleviation of respiratory diseases;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device; Nebulizers for respiratory therapy;

ONLIZUM

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

ONSPRYA

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder, pharmaceutical preparations and substances for the treatment and/or alleviation of respiratory diseases;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device; Nebulizers for respiratory therapy;

ONSPRYA

Antihistamines, nasal steroids, and nasal spray preparations for treatment of respiratory disorders;

OQIZA

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

RHINUET

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device;

RYALTRIS

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device;

RYALTRIS

Antihistamines, nasal steroids, and nasal spray preparations for treatment of respiratory disorders;

RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word RYALTRIS in purple, next to the word RYALTRIS on the same line are three imperfect intertwined circles where the top circle is green, the middle circle is purple, and the bottom circle is light blue (which also may be perceived as teal), and words (olopatadine hydrochloride and mometasone furoate) in black underneath RYALTRIS, this wording appears in the upper portion of the front and back panels, right to the light blue arch; the back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The background of the panels is white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word Ryaltris in purple above the words (olopatadine hydrochloride and mometasone furoate) in black. This wording appears in the upper portion of the front and back panels, right to the light blue arch. The back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The backgrounds of the panels are white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word RYALTRIS in purple, next to the word RYALTRIS on the same line are three imperfect intertwined circles where the top circle is green, the middle circle is purple, and the bottom circle is light blue (which also may be perceived as teal), and words (olopatadine hydrochloride and mometasone furoate) in black underneath RYALTRIS, this wording appears in the upper portion of the front and back panels, right to the light blue arch; the back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The background of the panels is white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

RYALTRIS (OLOPATADINE HYDROCHLORIDE ANDMOMETASONE FUROATE)

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word Ryaltris in purple above the words (olopatadine hydrochloride and mometasone furoate) in black. This wording appears in the upper portion of the front and back panels, right to the light blue arch. The back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The backgrounds of the panels are white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

RYALTRIS OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word Ryaltris in purple above the words (olopatadine hydrochloride and mometasone furoate) in black. This wording appears in the upper portion of the front and back panels, right to the light blue arch. The back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The backgrounds of the panels are white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

RYALTRIS OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE

The mark consists of a three-dimensional trade dress packaging carton for the goods, in which the front and left side panels feature colored overlapping arches, colored purple (Pantone code PMS 682), light blue (Pantone code PMS 311) and light green (Pantone code PMS 374), the colors are fading toward the wide parts of the arches. The front panel and back panel feature the stylized word RYALTRIS in purple, next to the word RYALTRIS on the same line are three imperfect intertwined circles where the top circle is green, the middle circle is purple, and the bottom circle is light blue (which also may be perceived as teal), and words (olopatadine hydrochloride and mometasone furoate) in black underneath RYALTRIS, this wording appears in the upper portion of the front and back panels, right to the light blue arch; the back panel of carton features the same colored arches, but they are wider at the place of overlap and only part of the light blue arch slightly overruns on the right panel on one side and parts of the light blue and light green arches from the front panel appear a little on the other side, at the bottom, whereas most of the right panel does not feature any elements of the trade dress. The background of the panels is white. The matter shown by the broken or dotted lines is not a part of the mark and serves only to show the position of the mark.;Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder; Antihistamine delivery device sold filled; nasal steroid delivery device sold filled;The color(s) purple, light blue, light green, black and white is/are claimed as a feature of the mark.;Antihistamine delivery device sold empty; nasal steroid delivery device sold empty; nasal spray preparation delivery device sold empty;OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE;

TEOBU

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

TULETYO

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

TULIZIO

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

TYNEBLER

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

TYOVIGA

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

TYPULMIS

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease;Nebulizers for respiratory therapy;

UCABRI

Pharmaceutical preparations for the prevention and treatment of Chronic Idiopathic Urticaria; Pharmaceutical preparations and substances for treatment and/or alleviation of Rhinitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Asthma; Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and Chronic Obstructive Pulmonary Disease; Pharmaceutical preparations and substances for treatment and/or alleviation of IGE-mediated disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Atopic Dermatitis; Pharmaceutical preparations and substances for treatment and/or alleviation of Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and other musculoskeletal disorders; Pharmaceutical preparations and substances for treatment and/or alleviation of Systemic Lupus Erythematosus;

XPAERO

Antihistamine, nasal steroid, nasal spray product for treatment of respiratory disorder;Antihistamine delivery device; nasal steroid delivery device; nasal spray preparation delivery device;

XYNCTIO

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease; all of the foregoing excluding, Pharmaceutical preparations acting on the central nervous system, pharmaceutical preparations for use in the treatment and/or management of sleep disorders, and neurological disorders;Nebulizers for respiratory therapy;

ZYNCTIO

Pharmaceutical preparations and substances for treatment and/or alleviation of respiratory ailments and chronic obstructive pulmonary disease; Inhalers filled with pharmaceutical preparations for the treatment and alleviation of respiratory ailments and chronic obstructive pulmonary disease; all of the foregoing excluding, Pharmaceutical preparations acting on the central nervous system, pharmaceutical preparations for use in the treatment and/or management of sleep disorders, and neurological disorders;Nebulizers for respiratory therapy;